CMA fines firms over £35m for illegal arrangement for NHS drug | Competition & Markets Authority

The CMA has fined firms over £35 million for an illegal arrangement in the supply of important NHS prescription anti-nausea tablets.

Related Keywords

United Kingdom ,Andrea Coscelli ,Cinven Luxco ,Meiji Seika Pharma Co ,Mercury Pharma Group ,Meiji Holdings Co Ltd ,Cinven Partners ,Medreich Ltd ,Alliance Pharmaceuticals ,Advanz Pharma Corp ,Lexon United Kingdom Holdings ,Alliance Pharma ,Meiji Holdings Co ,Pharma Holdings ,Concordia Investment Holdings United Kingdom ,Concordia Investments Jersey ,Lexon United Kingdom ,Markets Authority ,Chief Executive ,Competition Appeal Tribunal ,Alliance Pharmaceuticals Limited ,Focus Pharmaceuticals Limited ,Focus Pharma Holdings Limited ,Mercury Pharma Group Limited ,Concordia Investment Holdings ,Concordia Investments ,Advanz Pharma ,Cinven Capital Management ,General Partner Limited ,Lexon United Kingdom Holdings Limited ,Meiji Seika Pharma ,Meiji Holdings ,Competition Act ,Pharmaceuticals Limited ,Capital Management ,Limited ,Focus ,Cma ,Cinven ,Medreich ,Pharma ,Silexon ,Holdings ,Alliance ,Pharmaceuticals ,Advanz ,Nhs ,Uk ,February ,Competition ,Concordia ,Group ,July ,Meiji ,Mercury ,